Emerging therapies for axial spondyloarthritis, including SIMPONI (golimumab), XELJANZ (tofacitinib), CIMZIA (certolizumab pegol), ENBREL (etanercept), RINVOQ (upadacitinib), COSENTYX (secukinumab), TALTZ (ixekizumab), LUMICEF (brodalumab), BIMZELX (bimekizumab), and others, are expected to drive growth in the axial spondyloarthritis market in the coming years.
DelveInsight has published a new report, “Axial Spondyloarthritis – Market Insights, Epidemiology, and Market Forecast 2034”, offering detailed insights into the disease, including historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Discover about the Axial spondyloarthritis market report
During the ERS Congress 2025 in September 2025, several biotechnology and pharmaceutical companies shared notable advancements in pulmonary and cardiopulmonary research:
-
In September 2025, Diagonal Therapeutics presented new preclinical data highlighting the potential of its lead clustering antibody, DIAG723, as a disease-modifying therapy for pulmonary arterial hypertension (PAH).
-
In September 2025, a study revealed that babies raised with dogs may have a reduced risk of developing childhood asthma.
-
In September 2025, Savara shared data from the Phase 3 IMPALA-2 trial of Molgramostim Inhalation Solution for patients with autoimmune pulmonary alveolar proteinosis (aPAP).
-
In September 2025, AllRock Bio, Inc. reported encouraging Phase 1 results for ROC-101, a first-in-class oral pan-ROCK inhibitor for cardiopulmonary and fibrotic diseases.
-
In September 2025, Gossamer Bio, Inc., in collaboration with Chiesi Group, announced five scientific presentations on seralutinib for PAH and PH-ILD.
-
In September 2025, Boehringer Ingelheim presented pooled analyses from the Phase III FIBRONEER™ program on nerandomilast, an investigational oral PDE4B inhibitor, showing a nominally significant reduction in mortality risk across IPF and PPF.
-
In September 2025, Kaia Health launched a pilot program of Kaia Breathe, a digital pulmonary rehabilitation solution for COPD patients, in partnership with MedImprove.
-
In September 2025, aTyr Pharma, Inc. shared additional findings from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a key form of interstitial lung disease.
Some of the key facts of the Axial spondyloarthritis Market Report:
-
The axial spondyloarthritis (axSpA) market is expected to expand at a robust compound annual growth rate (CAGR) between 2020 and 2034. AxSpA is a complex inflammatory disorder primarily affecting the sacroiliac joints and spine, causing bone erosion and abnormal bone formation that may eventually lead to ankylosis. Its development is influenced by genetic, immunological, mechanical, and environmental factors, with HLA-B27 being the most prominent genetic contributor, alongside others such as ERAP1 and interleukin-related genes (IL-12, IL-17, IL-23). Importantly, axSpA can occur even in the absence of HLA-B27.
-
AxSpA is classified into two forms: non-radiographic axial spondyloarthritis (nr-axSpA) and radiographic axial spondyloarthritis (r-axSpA), the latter also known as ankylosing spondylitis (AS). According to DelveInsight, there were approximately 4.58 million prevalent axSpA cases across the 7MM in 2023, with significant growth expected through 2034. The U.S. holds the largest market share, followed by the EU4, the UK, and Japan, where around 21,300 cases were reported in 2023. HLA-B27 is particularly associated with higher rates of diagnosed AS compared to other genetic markers.
-
Currently approved therapies for AS include ENBREL (etanercept), XELJANZ (tofacitinib), and SIMPONI (golimumab), while in Japan, LUMICEF is approved for both axSpA subtypes. Recent approvals include BIMZELX (bimekizumab), authorized by Japan’s Ministry of Health in December 2023 and the European Commission in June 2023, for adults with active nr-axSpA and AS unresponsive to standard therapies.
-
While multiple treatments exist to manage symptoms and slow disease progression, no cure is currently available, and the pipeline for new axSpA therapies remains limited. DelveInsight estimates that around 569,000 individuals in the U.S. were diagnosed with nr-axSpA in 2023. In September 2024, the FDA approved Bimzelx, UCB’s dual IL‑17A/IL‑17F inhibitor, for treating active AS and nr‑axSpA in adults—the first therapy addressing the full spectrum of axSpA. Earlier in February 2024, the FDA accepted UCB’s supplemental biologics license application (sBLA) for Bimzelx, extending its indications to include AS, nr‑axSpA, and psoriatic arthritis (PsA).
-
Key companies driving axSpA research and development include UCB, AbbVie, Pfizer, Amgen, Janssen Biotech, Pozen, Iroko Pharmaceuticals, Syntex Pharmaceuticals, Horizon Pharma, Eli Lilly, Kyowa Kirin, Celgene, Inmagene Biopharmaceuticals, and others. Promising therapies in the market and pipeline include SIMPONI (golimumab), XELJANZ (tofacitinib), CIMZIA (certolizumab pegol), ENBREL (etanercept), RINVOQ (upadacitinib), COSENTYX (secukinumab), TALTZ (ixekizumab), LUMICEF (brodalumab), BIMZELX (bimekizumab), among others.
Axial Spondyloarthritis Overview
Axial spondyloarthritis (AxSpA) is a type of arthritis that primarily targets the spine and sacroiliac joints, which connect the spine to the pelvis, leading to pain and inflammation. It can also affect other joints and organs, making it a systemic condition. AxSpA often has a genetic component and is categorized into two forms: ankylosing spondylitis (radiographic AxSpA), where joint damage is visible on X-rays, and non-radiographic AxSpA, which may only be detected through MRI. The disease typically manifests between ages 20 and 40, with ankylosing spondylitis more common in men, while non-radiographic AxSpA affects men and women equally.
The axial spondyloarthritis report provides a detailed overview of the disease’s pathophysiology, diagnostic approaches, and treatment options. It also highlights the real-world patient journey, covering symptom onset, time to diagnosis, treatment initiation, and ongoing disease management.
Axial Spondyloarthritis Market Outlook
The axial spondyloarthritis market across the seven major markets is expected to see substantial growth beginning in 2024.
The United States accounts for the largest market share, followed by the EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. Within the EU4 and UK, Germany leads in market size, followed by Spain, while France represents the smallest segment.
In 2023, the total market value for axial spondyloarthritis therapies was around USD 9 million, with conventional treatments making up the majority of this figure.
Discover how the Axial spondyloarthritis market is rising in the coming years @ https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Axial Spondyloarthritis Marketed Drugs
-
SIMPONI (golimumab): Janssen Pharmaceuticals
-
XELJANZ (tofacitinib): Pfizer
Scope of the Axial Spondyloarthritis Market Report
-
Study Period: 2020-2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Axial spondyloarthritis Companies: UCB, AbbVie, Pfizer, Amgen, Janssen Biotech, Pozen, Iroko Pharmaceuticals, Syntex Pharmaceuticals, Horizon Pharma, Eli Lilly and Company, Kyowa Kirin, AbbVie, Celgene, Inmagene Biopharmaceuticals, and others
-
Axial spondyloarthritis Therapies: SIMPONI (golimumab), XELJANZ (tofacitinib), CIMZIA (certolizumab pegol), ENBREL (Etanercept), RINVOQ (Upadacitinib), COSENTYX (secukinumab), TALTZ (Ixekizumab), LUMICEF (brodalumab), BIMZELX (bimekizumab), and others.
-
Axial spondyloarthritis Therapeutic Assessment: Axial spondyloarthritis current marketed and Axial spondyloarthritis emerging therapies
-
Axial spondyloarthritis Market Dynamics: Axial spondyloarthritis market drivers and Axial spondyloarthritis market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
-
Axial spondyloarthritis Unmet Needs, KOL's views, Analyst's views, Axial spondyloarthritis Market Access and Reimbursement
To know what’s more in our Axial spondyloarthritis report, visit https://www.delveinsight.com/report-store/axial-spondyloarthritis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key benefits of the Axial Spondyloarthritis Market Report:
-
Axial spondyloarthritis market report covers a descriptive overview and comprehensive insight of the Axial spondyloarthritis Epidemiology and Axial spondyloarthritis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
-
The Axial spondyloarthritis market report provides insights into the current and emerging therapies.
-
The Axial spondyloarthritis market report provides a global historical and forecasted market covering drug outreach in 7MM.
-
The Axial spondyloarthritis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Axial spondyloarthritis market.
Got queries? Click here to know more about the Axial spondyloarthritis market Landscape
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Axial Spondyloarthritis Patient Share (%) Overview at a Glance
5. Axial Spondyloarthritis Market Overview at a Glance
6. Axial Spondyloarthritis Disease Background and Overview
7. Axial Spondyloarthritis Epidemiology and Patient Population
8. Country-Specific Patient Population of Axial Spondyloarthritis
9. Axial Spondyloarthritis Current Treatment and Medical Practices
10. Unmet Needs
11. Axial Spondyloarthritis Emerging Therapies
12. Axial Spondyloarthritis Market Outlook
13. Country-Wise Axial Spondyloarthritis Market Analysis (2020–2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Axial Spondyloarthritis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Axial spondyloarthritis Market Outlook 2034
Related Reports:
Axial Spondyloarthritis Pipeline Insights, DelveInsight
"Axial spondyloarthritis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Axial spondyloarthritis market. A detailed picture of the Axial spondyloarthritis pipeline landscape is provided, which includes the disease overview and Axial spondyloarthritis treatment guidelines.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
